Device type · QLU
Anti-Factor Xa Activity Test System, Apixaban
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
QLU
Hematology
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Anti-Factor Xa Activity Test System, Apixaban
- Product code
- QLU
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7295
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for QLU
Latest FDA decisions
Siemens Healthcare Diagnostics Products GmbH
K240315 · Decided Oct 10, 2024 · 251 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
- HemosIL Liquid Anti-Xa510(k)
K223187 · Decided Jun 23, 2023 · 254 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
- HemosIL Liquid Anti-XaNew device typeDe Novo
DEN190032 · Decided Sep 17, 2020 · 450 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0150-2022 · Started Aug 25, 2021
Reason given: Labeled On-board instrument stability issue for current and future lots, reduced On-board Instrument Stability from 7 days to 5 days
Cause as FDA categorized it: Device Design
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.